Castellano | Euskara | Français | English
DAR No 1. Pitavastatin (Alipzal®, Livazo®) in dyslipidemia
Share it
The eighth statin but no results on morbidity and mortality
- Pitavastatin has not been shown to be superior to other compared statins in the reduction of lipid levels. Unlike these other statins, there are no trials on mortality and morbidity with respect to pitavastatin.
- Adverse reactions are similar to the rest of the statins and the incidence tends to be dose-dependent.
- Clinically significant interactions have been observed with ciclosporin, erythromycin, rifampicin, warfarin and fibrates. Like fluvastatin and pravastatin, it is minimally metabolized via P450 cytochrome.
- It is more expensive than simvastatin and atorvastatin.
